Small Dose, Big Impact: HAMSYL Junior to Revolutionize Paediatric Cancer Care Paediatric Pegaspargase Breakthrough: Gennova introduces HAMSYL- Junior, the India’s first-ever 1500 IU paediatric pack size reshaping paediatric oncology care. Tailored for India's Young Warriors: Addressing wastage concerns and vial sharing, HAMSYL Junior, with a
CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. • Funding will support optimisation of the technology platform to enhance immunogenicity. 8 August 2023, OSLO Norway: The Coalition for Epidemic
